BiotechTube

exenatide + Other antidiabetic therapies

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies)

Conditions

Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)

Trial Timeline

Sep 1, 2004 → Mar 1, 2008

NCT ID
NCT01077323

About exenatide + Other antidiabetic therapies

exenatide + Other antidiabetic therapies is a pre-clinical stage product being developed by Eli Lilly for Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies). The current trial status is completed. This product is registered under clinical trial identifier NCT01077323. Target conditions include Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies).

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT01077323Pre-clinicalCompleted

Competing Products

20 competing products in Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies)

See all competitors
ProductCompanyStageHype Score
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
77
MKP10241 + PlaceboMankind PharmaPhase 2
52
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
33
LY3209590 + Insulin DegludecEli LillyPhase 1
33
AC2993Eli LillyPhase 3
77
LY3209590 + PlaceboEli LillyPhase 1
33
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
77
LY2963016 + LantusEli LillyPhase 1
33
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
23
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
85
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
77
Retatrutide + PlaceboEli LillyPhase 1
33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePrecigenPhase 1/2
36
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
33
Placebo + LinagliptinEli LillyPhase 3
77
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
85
teplizumab or placeboEli LillyPhase 1
33
LY2428757 + PlaceboEli LillyPhase 2
52
Insulin Efsitora Alfa + Insulin DegludecEli LillyPhase 3
77
LY900014 (SC) + LY900014 (IV)Eli LillyPhase 1
33

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85